Phase 1 Trial of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
Latest Information Update: 23 Dec 2022
Price :
$35 *
At a glance
- Drugs ION 537 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 20 Dec 2022 Status changed from recruiting to completed.
- 12 Dec 2020 New trial record
- 09 Dec 2020 Status changed from not yet recruiting to recruiting.